{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/clomipramine",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701413",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701413_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"St John's Wort\" outputclass=\"int-drug\">St John's Wort</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  St John's Wort  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's Wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701414",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701414_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"acebutolol\" outputclass=\"int-drug\">acebutolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  acebutolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acebutolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701415",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701415_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">aceclofenac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  aceclofenac  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aceclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701416",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701416_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"aclidinium\" outputclass=\"int-drug\">aclidinium</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  aclidinium  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aclidinium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701417",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701417_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">Clomipramine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"adrenaline/epinephrine\" outputclass=\"int-drug\">adrenaline/epinephrine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Clomipramine   increases   the effects of   adrenaline/epinephrine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Adrenaline/epinephrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701418",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701418_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"alcohol (beverage)\" outputclass=\"int-drug\">alcohol (beverage)</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  alcohol (beverage)  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alcohol (beverage)</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701419",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701419_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"alfuzosin\" outputclass=\"int-drug\">alfuzosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  alfuzosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alfuzosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701420",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701420_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"aliskiren\" outputclass=\"int-drug\">aliskiren</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  aliskiren  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aliskiren</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701421",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701421_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"almotriptan\" outputclass=\"int-drug\">almotriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  almotriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Almotriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701422",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701422_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"alprostadil\" outputclass=\"int-drug\">alprostadil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  alprostadil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alprostadil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701423",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701423_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"amantadine\" outputclass=\"int-drug\">amantadine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  amantadine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701423_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"amantadine\" outputclass=\"int-drug\">amantadine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  amantadine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amantadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701424",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701424_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"amifampridine\" outputclass=\"int-drug\">amifampridine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  amifampridine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amifampridine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701425",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701425_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"amiloride\" outputclass=\"int-drug\">amiloride</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  amiloride  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701426",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701426_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"aminophylline\" outputclass=\"int-drug\">Aminophylline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Aminophylline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aminophylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701427",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701427_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"amiodarone\" outputclass=\"int-drug\">amiodarone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  amiodarone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiodarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701428",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701428_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"amisulpride\" outputclass=\"int-drug\">amisulpride</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  amisulpride  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amisulpride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701429",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701429_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"amlodipine\" outputclass=\"int-drug\">amlodipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  amlodipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amlodipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701430",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701430_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"amphotericin\" outputclass=\"int-drug\">Amphotericin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Amphotericin   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amphotericin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701431",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701431_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  anagrelide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anagrelide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701432",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701432_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"apalutamide\" outputclass=\"int-drug\">apalutamide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  apalutamide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701433",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701433_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"apomorphine\" outputclass=\"int-drug\">apomorphine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  apomorphine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701433_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"apomorphine\" outputclass=\"int-drug\">apomorphine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  apomorphine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apomorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701434",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701434_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"apraclonidine\" outputclass=\"int-drug\">apraclonidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  apraclonidine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apraclonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701435",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701435_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"aripiprazole\" outputclass=\"int-drug\">aripiprazole</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  aripiprazole  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aripiprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701436",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701436_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"arsenic trioxide\" outputclass=\"int-drug\">arsenic trioxide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  arsenic trioxide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Arsenic trioxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701437",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701437_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"artemether\" outputclass=\"int-drug\">artemether</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  artemether  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Artemether</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701438",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701438_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"artenimol\" outputclass=\"int-drug\">artenimol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  artenimol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Artenimol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701439",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701439_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"asenapine\" outputclass=\"int-drug\">asenapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  asenapine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Asenapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701440",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701440_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"atenolol\" outputclass=\"int-drug\">atenolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  atenolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atenolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701441",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701441_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"atropine\" outputclass=\"int-drug\">atropine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  atropine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atropine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701442",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701442_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"avanafil\" outputclass=\"int-drug\">avanafil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  avanafil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Avanafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701443",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701443_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"azilsartan\" outputclass=\"int-drug\">azilsartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  azilsartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azilsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701444",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701444_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"baclofen\" outputclass=\"int-drug\">baclofen</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  baclofen  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701444_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"baclofen\" outputclass=\"int-drug\">baclofen</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  baclofen  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Baclofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701445",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701445_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bambuterol\" outputclass=\"int-drug\">Bambuterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bambuterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bambuterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701446",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701446_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"beclometasone\" outputclass=\"int-drug\">Beclometasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Beclometasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Beclometasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701447",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701447_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"bedaquiline\" outputclass=\"int-drug\">bedaquiline</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  bedaquiline  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bedaquiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701448",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701448_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  bendroflumethiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701448_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  bendroflumethiazide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701448_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">Bendroflumethiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Bendroflumethiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701449",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701449_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"benperidol\" outputclass=\"int-drug\">benperidol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  benperidol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Benperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701450",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701450_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"betamethasone\" outputclass=\"int-drug\">Betamethasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Betamethasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701451",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701451_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"betaxolol\" outputclass=\"int-drug\">betaxolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  betaxolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betaxolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701452",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701452_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"bisoprolol\" outputclass=\"int-drug\">bisoprolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  bisoprolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bisoprolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701453",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701453_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"bortezomib\" outputclass=\"int-drug\">bortezomib</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  bortezomib  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bortezomib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701454",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701454_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  bosutinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701455",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701455_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"brimonidine\" outputclass=\"int-drug\">brimonidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  brimonidine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Brimonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701456",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701456_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"bromocriptine\" outputclass=\"int-drug\">bromocriptine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  bromocriptine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bromocriptine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701457",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701457_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"budesonide\" outputclass=\"int-drug\">Budesonide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Budesonide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Budesonide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701458",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701458_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">bumetanide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  bumetanide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701458_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">bumetanide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  bumetanide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701458_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">Bumetanide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Bumetanide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bumetanide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701459",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701459_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"bupropion\" outputclass=\"int-drug\">bupropion</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  bupropion  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701459_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bupropion\" outputclass=\"int-drug\">Bupropion</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor for toxicity and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Bupropion   is predicted to   increase   the exposure to   clomipramine .  Manufacturer advises monitor for toxicity and adjust dose .    \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bupropion</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701460",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701460_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"buspirone\" outputclass=\"int-drug\">buspirone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  buspirone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Buspirone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701461",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701461_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"cabergoline\" outputclass=\"int-drug\">cabergoline</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  cabergoline  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabergoline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701462",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701462_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  cabozantinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701463",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701463_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"canagliflozin\" outputclass=\"int-drug\">canagliflozin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  canagliflozin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Canagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701464",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701464_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"candesartan\" outputclass=\"int-drug\">candesartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  candesartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Candesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701465",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701465_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"captopril\" outputclass=\"int-drug\">captopril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  captopril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Captopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701466",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701466_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">carbamazepine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  carbamazepine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701466_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Carbamazepine   decreases   the exposure to   clomipramine .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701467",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701467_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"cariprazine\" outputclass=\"int-drug\">cariprazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  cariprazine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cariprazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701468",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701468_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"carvedilol\" outputclass=\"int-drug\">carvedilol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  carvedilol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carvedilol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701469",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701469_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">celecoxib</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  celecoxib  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701470",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701470_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"celiprolol\" outputclass=\"int-drug\">celiprolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  celiprolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celiprolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701471",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701471_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"ceritinib\" outputclass=\"int-drug\">ceritinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  ceritinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceritinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701472",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701472_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  chlorothiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701472_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  chlorothiazide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701472_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">Chlorothiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Chlorothiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701473",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701473_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"chlorphenamine\" outputclass=\"int-drug\">chlorphenamine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  chlorphenamine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorphenamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701474",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701474_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  chlorpromazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701474_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  chlorpromazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701474_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  clomipramine  and  chlorpromazine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorpromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701475",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701475_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  chlortalidone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701475_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  chlortalidone  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701475_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">Chlortalidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Chlortalidone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701476",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701476_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"cimetidine\" outputclass=\"int-drug\">Cimetidine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Cimetidine   increases   the exposure to   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cimetidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701477",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701477_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"cinacalcet\" outputclass=\"int-drug\">Cinacalcet</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor for toxicity and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Cinacalcet   is predicted to   increase   the exposure to   clomipramine .  Manufacturer advises monitor for toxicity and adjust dose .    \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cinacalcet</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701478",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701478_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  citalopram  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701478_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  citalopram  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701478_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Both  clomipramine  and  citalopram  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701479",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701479_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">clarithromycin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  clarithromycin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701480",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701480_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"clemastine\" outputclass=\"int-drug\">clemastine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  clemastine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clemastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701481",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701481_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"clevidipine\" outputclass=\"int-drug\">clevidipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  clevidipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clevidipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701482",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701482_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"clonidine\" outputclass=\"int-drug\">clonidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  clonidine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701482_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">Clomipramine</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the antihypertensive effects of</ph> <ph otherprops=\"clonidine\" outputclass=\"int-drug\">clonidine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Clomipramine   decreases   the antihypertensive effects of   clonidine .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701483",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701483_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"clozapine\" outputclass=\"int-drug\">clozapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  clozapine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701483_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"clozapine\" outputclass=\"int-drug\">clozapine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  clozapine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clozapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701484",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701484_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"cobicistat\" outputclass=\"int-drug\">Cobicistat</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Cobicistat   is predicted to   slightly   increase   the exposure to   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobicistat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701485",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701485_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"crizotinib\" outputclass=\"int-drug\">crizotinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  crizotinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crizotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701486",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701486_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"cyclizine\" outputclass=\"int-drug\">cyclizine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  cyclizine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyclizine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701487",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701487_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"cyclopentolate\" outputclass=\"int-drug\">cyclopentolate</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  cyclopentolate  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyclopentolate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701488",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701488_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"cyproheptadine\" outputclass=\"int-drug\">cyproheptadine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  cyproheptadine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyproheptadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701489",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701489_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"dapagliflozin\" outputclass=\"int-drug\">dapagliflozin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  dapagliflozin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701490",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701490_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  dapoxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701490_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  dapoxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701491",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701491_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"darifenacin\" outputclass=\"int-drug\">darifenacin</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  darifenacin  can cause antimuscarinic effects. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701491_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"darifenacin\" outputclass=\"int-drug\">Darifenacin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Darifenacin   is predicted to   increase   the exposure to   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darifenacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701492",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701492_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  dasatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701493",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701493_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deflazacort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701494",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701494_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"delamanid\" outputclass=\"int-drug\">delamanid</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  delamanid  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Delamanid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701495",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701495_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"desflurane\" outputclass=\"int-drug\">desflurane</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  desflurane  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701496",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701496_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"desmopressin\" outputclass=\"int-drug\">desmopressin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  desmopressin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desmopressin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701497",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701497_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dexamethasone\" outputclass=\"int-drug\">Dexamethasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dexamethasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701498",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701498_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"dexamfetamine\" outputclass=\"int-drug\">dexamfetamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  dexamfetamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamfetamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701499",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701499_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"dexibuprofen\" outputclass=\"int-drug\">dexibuprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  dexibuprofen  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701500",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701500_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">dexketoprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  dexketoprofen  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701501",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701501_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"diazoxide\" outputclass=\"int-drug\">diazoxide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  diazoxide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diazoxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701502",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701502_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">diclofenac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  diclofenac  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701503",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701503_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"dicycloverine\" outputclass=\"int-drug\">dicycloverine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  dicycloverine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dicycloverine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701504",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701504_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"diltiazem\" outputclass=\"int-drug\">diltiazem</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  diltiazem  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diltiazem</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701505",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701505_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"dimenhydrinate\" outputclass=\"int-drug\">dimenhydrinate</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  dimenhydrinate  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dimenhydrinate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701506",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701506_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"dipyridamole\" outputclass=\"int-drug\">dipyridamole</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  dipyridamole  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipyridamole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701507",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701507_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"disopyramide\" outputclass=\"int-drug\">disopyramide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  disopyramide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701507_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"disopyramide\" outputclass=\"int-drug\">disopyramide</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  disopyramide  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Disopyramide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701508",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701508_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"domperidone\" outputclass=\"int-drug\">Domperidone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Domperidone   increases   the risk of QT-prolongation when given with   clomipramine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Domperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701509",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701509_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"doxazosin\" outputclass=\"int-drug\">doxazosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  doxazosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxazosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701510",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701510_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">dronedarone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  dronedarone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701510_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   clomipramine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronedarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701511",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701511_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"droperidol\" outputclass=\"int-drug\">droperidol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  droperidol  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701511_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"droperidol\" outputclass=\"int-drug\">droperidol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  droperidol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Droperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701512",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701512_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  duloxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701512_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  duloxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Duloxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701513",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701513_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"efavirenz\" outputclass=\"int-drug\">efavirenz</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  efavirenz  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Efavirenz</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701514",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701514_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"eletriptan\" outputclass=\"int-drug\">eletriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  eletriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eletriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701515",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701515_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"empagliflozin\" outputclass=\"int-drug\">empagliflozin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  empagliflozin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Empagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701516",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701516_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"enalapril\" outputclass=\"int-drug\">enalapril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  enalapril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enalapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701517",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701517_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"encorafenib\" outputclass=\"int-drug\">encorafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  encorafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Encorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701518",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701518_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">Clomipramine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"ephedrine\" outputclass=\"int-drug\">ephedrine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Clomipramine   is predicted to   decrease   the effects of   ephedrine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ephedrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701519",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701519_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  eplerenone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701519_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  eplerenone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eplerenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701520",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701520_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"eprosartan\" outputclass=\"int-drug\">eprosartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  eprosartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eprosartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701521",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701521_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"eribulin\" outputclass=\"int-drug\">eribulin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  eribulin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eribulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701522",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701522_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"ertugliflozin\" outputclass=\"int-drug\">ertugliflozin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  ertugliflozin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ertugliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701523",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701523_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"erythromycin\" outputclass=\"int-drug\">erythromycin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  erythromycin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erythromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701524",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701524_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  escitalopram  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701524_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  escitalopram  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701524_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Both  clomipramine  and  escitalopram  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701525",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701525_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"esketamine\" outputclass=\"int-drug\">esketamine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  esketamine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Esketamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701526",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701526_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"esmolol\" outputclass=\"int-drug\">esmolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  esmolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Esmolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701527",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701527_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"etodolac\" outputclass=\"int-drug\">etodolac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  etodolac  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etodolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701528",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701528_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"etomidate\" outputclass=\"int-drug\">etomidate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  etomidate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etomidate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701529",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701529_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">etoricoxib</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  etoricoxib  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoricoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701530",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701530_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"felodipine\" outputclass=\"int-drug\">felodipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  felodipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Felodipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701531",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701531_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"fentanyl\" outputclass=\"int-drug\">fentanyl</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  fentanyl  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fentanyl</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701532",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701532_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"fesoterodine\" outputclass=\"int-drug\">fesoterodine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  fesoterodine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fesoterodine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701533",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701533_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fingolimod\" outputclass=\"int-drug\">Fingolimod</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fingolimod   increases   the risk of QT-prolongation when given with   clomipramine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fingolimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701534",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701534_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"flavoxate\" outputclass=\"int-drug\">flavoxate</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  flavoxate  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flavoxate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701535",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701535_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"flecainide\" outputclass=\"int-drug\">flecainide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  flecainide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flecainide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701536",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701536_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">fluconazole</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  fluconazole  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701537",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701537_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fludrocortisone\" outputclass=\"int-drug\">Fludrocortisone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fludrocortisone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701538",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701538_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  fluoxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701538_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  fluoxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701538_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">Fluoxetine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor for toxicity and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Fluoxetine   is predicted to   increase   the exposure to   clomipramine .  Manufacturer advises monitor for toxicity and adjust dose .    \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701539",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701539_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"flupentixol\" outputclass=\"int-drug\">flupentixol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  flupentixol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flupentixol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701540",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701540_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"fluphenazine\" outputclass=\"int-drug\">fluphenazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  fluphenazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701540_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"fluphenazine\" outputclass=\"int-drug\">fluphenazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  fluphenazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluphenazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701541",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701541_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">flurbiprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  flurbiprofen  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flurbiprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701542",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701542_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  fluvoxamine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701542_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  fluvoxamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701542_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">Fluvoxamine</ph> <ph outputclass=\"int-magnitude\">markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Fluvoxamine   markedly   increases   the exposure to   clomipramine .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvoxamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701543",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701543_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"formoterol\" outputclass=\"int-drug\">Formoterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Formoterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Formoterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701544",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701544_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"fosinopril\" outputclass=\"int-drug\">fosinopril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  fosinopril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701545",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701545_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"frovatriptan\" outputclass=\"int-drug\">frovatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  frovatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Frovatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701546",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701546_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"furosemide\" outputclass=\"int-drug\">furosemide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  furosemide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701546_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"furosemide\" outputclass=\"int-drug\">furosemide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  furosemide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701546_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"furosemide\" outputclass=\"int-drug\">Furosemide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Furosemide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701547",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701547_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"gabapentin\" outputclass=\"int-drug\">gabapentin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  gabapentin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gabapentin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701548",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701548_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"glyceryl trinitrate\" outputclass=\"int-drug\">glyceryl trinitrate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  glyceryl trinitrate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glyceryl trinitrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701549",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701549_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"glycopyrronium\" outputclass=\"int-drug\">glycopyrronium</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  glycopyrronium  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glycopyrronium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701550",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701550_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"granisetron\" outputclass=\"int-drug\">granisetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  granisetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701550_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"granisetron\" outputclass=\"int-drug\">Granisetron</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Granisetron   is predicted to   increase   the risk of QT-prolongation when given with   clomipramine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Granisetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701551",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701551_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"guanethidine\" outputclass=\"int-drug\">guanethidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  guanethidine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701551_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">Clomipramine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the antihypertensive effects of</ph> <ph otherprops=\"guanethidine\" outputclass=\"int-drug\">guanethidine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Clomipramine   is predicted to   decrease   the antihypertensive effects of   guanethidine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Guanethidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701552",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701552_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"guanfacine\" outputclass=\"int-drug\">guanfacine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  guanfacine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Guanfacine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701553",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701553_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  haloperidol  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701553_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  haloperidol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701553_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  clomipramine  and  haloperidol  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Haloperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701554",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701554_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"homatropine\" outputclass=\"int-drug\">homatropine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  homatropine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Homatropine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701555",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701555_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"hydralazine\" outputclass=\"int-drug\">hydralazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  hydralazine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydralazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701556",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701556_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  hydrochlorothiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701556_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  hydrochlorothiazide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701556_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">Hydrochlorothiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Hydrochlorothiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701557",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701557_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrocortisone\" outputclass=\"int-drug\">Hydrocortisone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydrocortisone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701558",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701558_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  hydroflumethiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701558_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  hydroflumethiazide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701558_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">Hydroflumethiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Hydroflumethiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701559",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701559_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"hydroxyzine\" outputclass=\"int-drug\">hydroxyzine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  hydroxyzine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701559_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"hydroxyzine\" outputclass=\"int-drug\">hydroxyzine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  hydroxyzine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxyzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701560",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701560_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"hyoscine\" outputclass=\"int-drug\">hyoscine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  hyoscine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hyoscine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701561",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701561_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">ibuprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  ibuprofen  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701562",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701562_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"imidapril\" outputclass=\"int-drug\">imidapril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  imidapril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imidapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701563",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701563_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indacaterol\" outputclass=\"int-drug\">Indacaterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Indacaterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indacaterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701564",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701564_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  indapamide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701564_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  indapamide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701564_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indapamide\" outputclass=\"int-drug\">Indapamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Indapamide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701565",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701565_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"indometacin\" outputclass=\"int-drug\">indometacin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  indometacin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indometacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701566",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701566_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"indoramin\" outputclass=\"int-drug\">indoramin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  indoramin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indoramin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701567",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701567_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"inotuzumab ozogamicin\" outputclass=\"int-drug\">inotuzumab ozogamicin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  inotuzumab ozogamicin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotuzumab ozogamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701568",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701568_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"ipratropium\" outputclass=\"int-drug\">ipratropium</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  ipratropium  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ipratropium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701569",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701569_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"irbesartan\" outputclass=\"int-drug\">irbesartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  irbesartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irbesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701570",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701570_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"isocarboxazid\" outputclass=\"int-drug\">isocarboxazid</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  isocarboxazid  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701570_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"isocarboxazid\" outputclass=\"int-drug\">isocarboxazid</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  isocarboxazid  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701570_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">Clomipramine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of severe toxic reaction when given with</ph> <ph otherprops=\"isocarboxazid\" outputclass=\"int-drug\">isocarboxazid</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Clomipramine   is predicted to   increase   the risk of severe toxic reaction when given with   isocarboxazid .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isocarboxazid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701571",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701571_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"isoflurane\" outputclass=\"int-drug\">isoflurane</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  isoflurane  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isoflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701572",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701572_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"isosorbide dinitrate\" outputclass=\"int-drug\">isosorbide dinitrate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  isosorbide dinitrate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isosorbide dinitrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701573",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701573_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"isosorbide mononitrate\" outputclass=\"int-drug\">isosorbide mononitrate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  isosorbide mononitrate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isosorbide mononitrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701574",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701574_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ivabradine\" outputclass=\"int-drug\">Ivabradine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of torsade de pointes when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ivabradine   is predicted to   increase   the risk of torsade de pointes when given with   clomipramine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ivabradine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701575",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701575_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"ketamine\" outputclass=\"int-drug\">ketamine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  ketamine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701576",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701576_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">ketoprofen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  ketoprofen  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701577",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701577_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">ketorolac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  ketorolac  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketorolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701578",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701578_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"labetalol\" outputclass=\"int-drug\">labetalol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  labetalol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Labetalol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701579",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701579_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"lacidipine\" outputclass=\"int-drug\">lacidipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  lacidipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lacidipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701580",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701580_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"lapatinib\" outputclass=\"int-drug\">lapatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  lapatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lapatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701581",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701581_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"lenvatinib\" outputclass=\"int-drug\">lenvatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  lenvatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenvatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701582",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701582_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"lercanidipine\" outputclass=\"int-drug\">lercanidipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  lercanidipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lercanidipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701583",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701583_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"levobunolol\" outputclass=\"int-drug\">levobunolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  levobunolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levobunolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701584",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701584_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"levodopa\" outputclass=\"int-drug\">levodopa</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  levodopa  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701584_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">Clomipramine</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"levodopa\" outputclass=\"int-drug\">levodopa</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Clomipramine   decreases   the absorption of   levodopa .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levodopa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701585",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701585_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">levomepromazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  levomepromazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701585_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">levomepromazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  levomepromazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701585_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">levomepromazine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  clomipramine  and  levomepromazine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levomepromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701586",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701586_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"linezolid\" outputclass=\"int-drug\">linezolid</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  linezolid  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Linezolid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701587",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701587_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"lisdexamfetamine\" outputclass=\"int-drug\">lisdexamfetamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  lisdexamfetamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "175",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisdexamfetamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701588",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701588_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"lisinopril\" outputclass=\"int-drug\">lisinopril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  lisinopril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "176",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701589",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701589_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  lithium  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701589_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  lithium  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701589_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">Clomipramine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Clomipramine   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "177",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701590",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701590_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"lofexidine\" outputclass=\"int-drug\">lofexidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  lofexidine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701590_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"lofexidine\" outputclass=\"int-drug\">lofexidine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  lofexidine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "178",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lofexidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701591",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701591_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"losartan\" outputclass=\"int-drug\">losartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  losartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "179",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Losartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701592",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701592_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"loxapine\" outputclass=\"int-drug\">loxapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  loxapine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701592_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"loxapine\" outputclass=\"int-drug\">loxapine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  loxapine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "180",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Loxapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701593",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701593_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"lurasidone\" outputclass=\"int-drug\">lurasidone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  lurasidone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "181",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lurasidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701594",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701594_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">mefenamic acid</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  mefenamic acid  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "182",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701595",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701595_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mefloquine\" outputclass=\"int-drug\">Mefloquine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mefloquine   is predicted to   increase   the risk of QT-prolongation when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "183",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefloquine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701596",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701596_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">meloxicam</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  meloxicam  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "184",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meloxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701597",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701597_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  methadone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701597_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  methadone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "185",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methadone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701598",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701598_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"methoxyflurane\" outputclass=\"int-drug\">methoxyflurane</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  methoxyflurane  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "186",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methoxyflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701599",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701599_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"methyldopa\" outputclass=\"int-drug\">methyldopa</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  methyldopa  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "187",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methyldopa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701600",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701600_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"methylprednisolone\" outputclass=\"int-drug\">Methylprednisolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Methylprednisolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "188",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylprednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701601",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701601_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"methylthioninium chloride\" outputclass=\"int-drug\">methylthioninium chloride</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  methylthioninium chloride  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "189",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylthioninium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701602",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701602_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  metolazone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701602_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  metolazone  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701602_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"metolazone\" outputclass=\"int-drug\">Metolazone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Metolazone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "190",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701603",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701603_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"metoprolol\" outputclass=\"int-drug\">metoprolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  metoprolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "191",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metoprolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701604",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701604_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"mianserin\" outputclass=\"int-drug\">mianserin</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  mianserin  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "192",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mianserin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701605",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701605_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"minoxidil\" outputclass=\"int-drug\">minoxidil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  minoxidil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "193",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Minoxidil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701606",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701606_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"mirtazapine\" outputclass=\"int-drug\">mirtazapine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  mirtazapine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "194",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mirtazapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701607",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701607_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mizolastine\" outputclass=\"int-drug\">Mizolastine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mizolastine   is predicted to   increase   the risk of QT-prolongation when given with   clomipramine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "195",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mizolastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701608",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701608_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"moclobemide\" outputclass=\"int-drug\">moclobemide</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  moclobemide  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701608_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">Clomipramine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of severe toxic reaction when given with</ph> <ph otherprops=\"moclobemide\" outputclass=\"int-drug\">moclobemide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Clomipramine   is predicted to   increase   the risk of severe toxic reaction when given with   moclobemide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "196",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moclobemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701609",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701609_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"moxifloxacin\" outputclass=\"int-drug\">moxifloxacin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  moxifloxacin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "197",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxifloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701610",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701610_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"moxisylyte\" outputclass=\"int-drug\">moxisylyte</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  moxisylyte  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "198",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxisylyte</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701611",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701611_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"moxonidine\" outputclass=\"int-drug\">moxonidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  moxonidine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701611_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">Clomipramine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"moxonidine\" outputclass=\"int-drug\">moxonidine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Clomipramine   is predicted to   decrease   the effects of   moxonidine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "199",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701612",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701612_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">nabumetone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  nabumetone  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "200",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nabumetone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701613",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701613_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"nadolol\" outputclass=\"int-drug\">nadolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  nadolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "201",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nadolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701614",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701614_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"naproxen\" outputclass=\"int-drug\">naproxen</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  naproxen  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "202",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naproxen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701615",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701615_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"naratriptan\" outputclass=\"int-drug\">naratriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  naratriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "203",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naratriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701616",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701616_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"nebivolol\" outputclass=\"int-drug\">nebivolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  nebivolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "204",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nebivolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701617",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701617_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"nefopam\" outputclass=\"int-drug\">nefopam</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  nefopam  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "205",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nefopam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701618",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701618_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"nicardipine\" outputclass=\"int-drug\">nicardipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  nicardipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "206",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicardipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701619",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701619_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"nicorandil\" outputclass=\"int-drug\">nicorandil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  nicorandil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "207",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicorandil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701620",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701620_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"nifedipine\" outputclass=\"int-drug\">nifedipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  nifedipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "208",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nifedipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701621",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701621_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">nilotinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  nilotinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "209",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701622",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701622_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"nimodipine\" outputclass=\"int-drug\">nimodipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  nimodipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "210",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nimodipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701623",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701623_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"nitrous oxide\" outputclass=\"int-drug\">nitrous oxide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  nitrous oxide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "211",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nitrous oxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701624",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701624_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">Clomipramine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"noradrenaline/norepinephrine\" outputclass=\"int-drug\">noradrenaline/norepinephrine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Clomipramine   increases   the effects of   noradrenaline/norepinephrine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "212",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Noradrenaline/norepinephrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701625",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701625_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"olanzapine\" outputclass=\"int-drug\">olanzapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  olanzapine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "213",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olanzapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701626",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701626_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"olmesartan\" outputclass=\"int-drug\">olmesartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  olmesartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "214",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olmesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701627",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701627_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"olodaterol\" outputclass=\"int-drug\">Olodaterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Olodaterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "215",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olodaterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701628",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701628_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"ondansetron\" outputclass=\"int-drug\">ondansetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  ondansetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701628_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"ondansetron\" outputclass=\"int-drug\">ondansetron</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  ondansetron  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "216",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ondansetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701629",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701629_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"orphenadrine\" outputclass=\"int-drug\">orphenadrine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  orphenadrine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "217",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Orphenadrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701630",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701630_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"osimertinib\" outputclass=\"int-drug\">osimertinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  osimertinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "218",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Osimertinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701631",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701631_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"oxprenolol\" outputclass=\"int-drug\">oxprenolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  oxprenolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "219",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxprenolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701632",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701632_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"oxybutynin\" outputclass=\"int-drug\">oxybutynin</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  oxybutynin  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "220",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxybutynin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701633",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701633_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"paliperidone\" outputclass=\"int-drug\">paliperidone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  paliperidone  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701633_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"paliperidone\" outputclass=\"int-drug\">paliperidone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  paliperidone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "221",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paliperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701634",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701634_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"palonosetron\" outputclass=\"int-drug\">palonosetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  palonosetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701634_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"palonosetron\" outputclass=\"int-drug\">Palonosetron</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Palonosetron   is predicted to   increase   the risk of QT-prolongation when given with   clomipramine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "222",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Palonosetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701635",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701635_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"panobinostat\" outputclass=\"int-drug\">panobinostat</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  panobinostat  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "223",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Panobinostat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701636",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701636_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">parecoxib</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  parecoxib  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "224",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Parecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701637",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701637_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  paroxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701637_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  paroxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701637_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">Paroxetine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor for toxicity and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Paroxetine   is predicted to   increase   the exposure to   clomipramine .  Manufacturer advises monitor for toxicity and adjust dose .    \n\n"
						}
					],
					"hasOrder": "225",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701638",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701638_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"pasireotide\" outputclass=\"int-drug\">pasireotide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  pasireotide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "226",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pasireotide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701639",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701639_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  pazopanib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "227",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701640",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701640_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Intravenous</ph> <ph otherprops=\"pentamidine\" outputclass=\"int-drug\">pentamidine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Intravenous   pentamidine   potentially   increases   the risk of QT-prolongation when given with   clomipramine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "228",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentamidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701641",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701641_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"pentazocine\" outputclass=\"int-drug\">pentazocine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  pentazocine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "229",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentazocine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701642",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701642_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"pergolide\" outputclass=\"int-drug\">pergolide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  pergolide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "230",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pergolide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701643",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701643_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"pericyazine\" outputclass=\"int-drug\">pericyazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  pericyazine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "231",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pericyazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701644",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701644_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"perindopril\" outputclass=\"int-drug\">perindopril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  perindopril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "232",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Perindopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701645",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701645_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"pethidine\" outputclass=\"int-drug\">pethidine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  pethidine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "233",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pethidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701646",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701646_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"phenelzine\" outputclass=\"int-drug\">phenelzine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  phenelzine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701646_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"phenelzine\" outputclass=\"int-drug\">phenelzine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  phenelzine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701646_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">Clomipramine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of severe toxic reaction when given with</ph> <ph otherprops=\"phenelzine\" outputclass=\"int-drug\">phenelzine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Clomipramine   is predicted to   increase   the risk of severe toxic reaction when given with   phenelzine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "234",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenelzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701647",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701647_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   decrease   the exposure to   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "235",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701648",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701648_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">Clomipramine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"phenylephrine\" outputclass=\"int-drug\">phenylephrine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Clomipramine   increases   the effects of   phenylephrine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "236",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenylephrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701649",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701649_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"pimozide\" outputclass=\"int-drug\">pimozide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  pimozide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701649_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"pimozide\" outputclass=\"int-drug\">pimozide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  pimozide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701649_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"pimozide\" outputclass=\"int-drug\">pimozide</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  clomipramine  and  pimozide  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "237",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pimozide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701650",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701650_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"pindolol\" outputclass=\"int-drug\">pindolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  pindolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "238",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pindolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701651",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701651_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">piroxicam</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  piroxicam  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "239",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Piroxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701652",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701652_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">Clomipramine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"pitolisant\" outputclass=\"int-drug\">pitolisant</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Clomipramine   is predicted to   decrease   the efficacy of   pitolisant .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "240",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pitolisant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701653",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701653_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"pramipexole\" outputclass=\"int-drug\">pramipexole</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  pramipexole  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "241",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pramipexole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701654",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701654_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"prazosin\" outputclass=\"int-drug\">prazosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  prazosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "242",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prazosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701655",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701655_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"prednisolone\" outputclass=\"int-drug\">Prednisolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Prednisolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "243",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701656",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701656_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   decrease   the exposure to   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "244",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701657",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701657_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"procarbazine\" outputclass=\"int-drug\">procarbazine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  procarbazine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "245",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Procarbazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701658",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701658_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"prochlorperazine\" outputclass=\"int-drug\">prochlorperazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  prochlorperazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701658_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"prochlorperazine\" outputclass=\"int-drug\">prochlorperazine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  prochlorperazine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "246",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prochlorperazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701659",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701659_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"procyclidine\" outputclass=\"int-drug\">procyclidine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  procyclidine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "247",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Procyclidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701660",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701660_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"promazine\" outputclass=\"int-drug\">promazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  promazine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "248",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Promazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701661",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701661_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"promethazine\" outputclass=\"int-drug\">promethazine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  promethazine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "249",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Promethazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701662",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701662_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"propafenone\" outputclass=\"int-drug\">propafenone</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  propafenone  can cause antimuscarinic effects. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701662_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"propafenone\" outputclass=\"int-drug\">Propafenone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Propafenone   is predicted to   increase   the concentration of   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "250",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propafenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701663",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701663_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"propantheline\" outputclass=\"int-drug\">propantheline</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  propantheline  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "251",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propantheline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701664",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701664_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"propiverine\" outputclass=\"int-drug\">propiverine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  propiverine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "252",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propiverine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701665",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701665_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"propofol\" outputclass=\"int-drug\">propofol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  propofol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "253",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propofol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701666",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701666_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"propranolol\" outputclass=\"int-drug\">propranolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  propranolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "254",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propranolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701667",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701667_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"quetiapine\" outputclass=\"int-drug\">quetiapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  quetiapine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "255",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quetiapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701668",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701668_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"quinagolide\" outputclass=\"int-drug\">quinagolide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  quinagolide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "256",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinagolide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701669",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701669_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"quinapril\" outputclass=\"int-drug\">quinapril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  quinapril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "257",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701670",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701670_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"quinine\" outputclass=\"int-drug\">quinine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  quinine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "258",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701671",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701671_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"ramipril\" outputclass=\"int-drug\">ramipril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  ramipril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "259",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ramipril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701672",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701672_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"ranolazine\" outputclass=\"int-drug\">ranolazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  ranolazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "260",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ranolazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701673",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701673_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"rasagiline\" outputclass=\"int-drug\">rasagiline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  rasagiline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "261",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rasagiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701674",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701674_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"ribociclib\" outputclass=\"int-drug\">ribociclib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  ribociclib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "262",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ribociclib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701675",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701675_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"riociguat\" outputclass=\"int-drug\">riociguat</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  riociguat  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "263",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Riociguat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701676",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701676_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"risperidone\" outputclass=\"int-drug\">risperidone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  risperidone  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701676_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"risperidone\" outputclass=\"int-drug\">risperidone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  risperidone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "264",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Risperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701677",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701677_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ritonavir\" outputclass=\"int-drug\">Ritonavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ritonavir   is predicted to   increase   the exposure to   clomipramine .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "265",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ritonavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701678",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701678_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"rizatriptan\" outputclass=\"int-drug\">rizatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  rizatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "266",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rizatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701679",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701679_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"ropinirole\" outputclass=\"int-drug\">ropinirole</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  ropinirole  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "267",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ropinirole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701680",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701680_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"rotigotine\" outputclass=\"int-drug\">rotigotine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  rotigotine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "268",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rotigotine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701681",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701681_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sacubitril\" outputclass=\"int-drug\">sacubitril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  sacubitril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "269",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sacubitril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701682",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701682_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"safinamide\" outputclass=\"int-drug\">safinamide</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  safinamide  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "270",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Safinamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701683",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701683_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"salbutamol\" outputclass=\"int-drug\">Salbutamol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Salbutamol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "271",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Salbutamol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701684",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701684_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"salmeterol\" outputclass=\"int-drug\">Salmeterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Salmeterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "272",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Salmeterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701685",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701685_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sapropterin\" outputclass=\"int-drug\">sapropterin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  sapropterin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "273",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sapropterin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701686",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701686_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"saquinavir\" outputclass=\"int-drug\">saquinavir</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  saquinavir  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "274",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Saquinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701687",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701687_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"selegiline\" outputclass=\"int-drug\">selegiline</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  selegiline  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701687_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"selegiline\" outputclass=\"int-drug\">selegiline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  selegiline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "275",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selegiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701688",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701688_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  sertraline  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701688_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  sertraline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "276",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sertraline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701689",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701689_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sevoflurane\" outputclass=\"int-drug\">sevoflurane</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  sevoflurane  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "277",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sevoflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701690",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701690_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sildenafil\" outputclass=\"int-drug\">sildenafil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  sildenafil  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701690_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sildenafil\" outputclass=\"int-drug\">sildenafil</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  sildenafil  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "278",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sildenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701691",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701691_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sodium nitroprusside\" outputclass=\"int-drug\">sodium nitroprusside</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  sodium nitroprusside  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "279",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium nitroprusside</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701692",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701692_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sodium oxybate\" outputclass=\"int-drug\">sodium oxybate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  sodium oxybate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "280",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium oxybate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701693",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701693_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sodium picosulfate\" outputclass=\"int-drug\">sodium picosulfate</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  sodium picosulfate  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "281",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium picosulfate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701694",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701694_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"solifenacin\" outputclass=\"int-drug\">solifenacin</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  solifenacin  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "282",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Solifenacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701695",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701695_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  sorafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "283",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701696",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701696_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sotalol\" outputclass=\"int-drug\">sotalol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  sotalol  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701696_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sotalol\" outputclass=\"int-drug\">sotalol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  sotalol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "284",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sotalol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701697",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701697_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  spironolactone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701697_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  spironolactone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "285",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Spironolactone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701698",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701698_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"sucralfate\" outputclass=\"int-drug\">Sucralfate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Sucralfate   is predicted to   decrease   the absorption of   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "286",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sucralfate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701699",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701699_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sulindac\" outputclass=\"int-drug\">sulindac</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  sulindac  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "287",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulindac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701700",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701700_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sulpiride\" outputclass=\"int-drug\">sulpiride</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  sulpiride  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701700_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sulpiride\" outputclass=\"int-drug\">sulpiride</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  sulpiride  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "288",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulpiride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701701",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701701_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sumatriptan\" outputclass=\"int-drug\">sumatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  sumatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "289",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sumatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701702",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701702_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  sunitinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "290",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701703",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701703_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tadalafil\" outputclass=\"int-drug\">tadalafil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  tadalafil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "291",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tadalafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701704",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701704_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tamsulosin\" outputclass=\"int-drug\">tamsulosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  tamsulosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "292",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tamsulosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701705",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701705_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tapentadol\" outputclass=\"int-drug\">tapentadol</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  tapentadol  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "293",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tapentadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701706",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701706_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"telavancin\" outputclass=\"int-drug\">telavancin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  telavancin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "294",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telavancin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701707",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701707_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"telmisartan\" outputclass=\"int-drug\">telmisartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  telmisartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "295",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telmisartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701708",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701708_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">tenoxicam</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  tenoxicam  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "296",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenoxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701709",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701709_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"terazosin\" outputclass=\"int-drug\">terazosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  terazosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "297",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Terazosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701710",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701710_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"terbinafine\" outputclass=\"int-drug\">Terbinafine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor for toxicity and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Terbinafine   is predicted to   increase   the exposure to   clomipramine .  Manufacturer advises monitor for toxicity and adjust dose .    \n\n"
						}
					],
					"hasOrder": "298",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Terbinafine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701711",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701711_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"terbutaline\" outputclass=\"int-drug\">Terbutaline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Terbutaline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "299",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Terbutaline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701712",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701712_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tetrabenazine\" outputclass=\"int-drug\">tetrabenazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  tetrabenazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "300",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tetrabenazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701713",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701713_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"theophylline\" outputclass=\"int-drug\">Theophylline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Theophylline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "301",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Theophylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701714",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701714_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"thiopental\" outputclass=\"int-drug\">thiopental</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  thiopental  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701714_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">Clomipramine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of cardiac arrhythmias and hypotension when given with</ph> <ph otherprops=\"thiopental\" outputclass=\"int-drug\">thiopental</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Clomipramine   increases   the risk of cardiac arrhythmias and hypotension when given with   thiopental .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "302",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thiopental</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701715",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701715_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">tiaprofenic acid</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  tiaprofenic acid  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "303",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tiaprofenic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701716",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701716_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"timolol\" outputclass=\"int-drug\">timolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  timolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "304",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Timolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701717",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701717_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tiotropium\" outputclass=\"int-drug\">tiotropium</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  tiotropium  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "305",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tiotropium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701718",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701718_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   is predicted to   increase   the exposure to   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "306",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701719",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701719_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tizanidine\" outputclass=\"int-drug\">tizanidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  tizanidine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701719_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tizanidine\" outputclass=\"int-drug\">tizanidine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  tizanidine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "307",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tizanidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701720",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701720_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">tolfenamic acid</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  tolfenamic acid  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "308",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolfenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701721",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701721_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tolterodine\" outputclass=\"int-drug\">tolterodine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  tolterodine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701721_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tolterodine\" outputclass=\"int-drug\">tolterodine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  tolterodine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "309",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolterodine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701722",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701722_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"torasemide\" outputclass=\"int-drug\">torasemide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  torasemide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701722_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"torasemide\" outputclass=\"int-drug\">torasemide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  torasemide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701722_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"torasemide\" outputclass=\"int-drug\">Torasemide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Torasemide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "310",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Torasemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701723",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701723_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"toremifene\" outputclass=\"int-drug\">toremifene</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  toremifene  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "311",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Toremifene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701724",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701724_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tramadol\" outputclass=\"int-drug\">tramadol</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  tramadol  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "312",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tramadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701725",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701725_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"trandolapril\" outputclass=\"int-drug\">trandolapril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  trandolapril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "313",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trandolapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701726",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701726_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tranylcypromine\" outputclass=\"int-drug\">tranylcypromine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  tranylcypromine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701726_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tranylcypromine\" outputclass=\"int-drug\">tranylcypromine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  tranylcypromine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701726_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">Clomipramine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of severe toxic reaction when given with</ph> <ph otherprops=\"tranylcypromine\" outputclass=\"int-drug\">tranylcypromine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid and for 14 days after stopping the MAOI</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Clomipramine   is predicted to   increase   the risk of severe toxic reaction when given with   tranylcypromine .  Manufacturer advises avoid and for 14 days after stopping the MAOI .    \n\n"
						}
					],
					"hasOrder": "314",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tranylcypromine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701727",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701727_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"trazodone\" outputclass=\"int-drug\">trazodone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  trazodone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "315",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trazodone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701728",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701728_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"triamcinolone\" outputclass=\"int-drug\">Triamcinolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Triamcinolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "316",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamcinolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701729",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701729_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"triamterene\" outputclass=\"int-drug\">triamterene</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  triamterene  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "317",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamterene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701730",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701730_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"trifluoperazine\" outputclass=\"int-drug\">trifluoperazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  trifluoperazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701730_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"trifluoperazine\" outputclass=\"int-drug\">trifluoperazine</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  trifluoperazine  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "318",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trifluoperazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701731",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701731_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"trihexyphenidyl\" outputclass=\"int-drug\">trihexyphenidyl</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  trihexyphenidyl  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "319",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trihexyphenidyl</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701732",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701732_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  trimethoprim  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "320",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimethoprim</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701733",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701733_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tropicamide\" outputclass=\"int-drug\">tropicamide</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  tropicamide  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "321",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tropicamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701734",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701734_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"trospium\" outputclass=\"int-drug\">trospium</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  trospium  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "322",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trospium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701735",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701735_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"tryptophan\" outputclass=\"int-drug\">tryptophan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  tryptophan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "323",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tryptophan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701736",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701736_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"umeclidinium\" outputclass=\"int-drug\">umeclidinium</ph> can cause antimuscarinic effects.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  umeclidinium  can cause antimuscarinic effects. \n\n"
						}
					],
					"hasOrder": "324",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Umeclidinium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701737",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701737_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"valsartan\" outputclass=\"int-drug\">valsartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  valsartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "325",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701738",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701738_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"vandetanib\" outputclass=\"int-drug\">vandetanib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  vandetanib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "326",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vandetanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701739",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701739_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"vardenafil\" outputclass=\"int-drug\">vardenafil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  vardenafil  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701739_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"vardenafil\" outputclass=\"int-drug\">vardenafil</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  vardenafil  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "327",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vardenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701740",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701740_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"vemurafenib\" outputclass=\"int-drug\">vemurafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  vemurafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "328",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vemurafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701741",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701741_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  venlafaxine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701741_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  venlafaxine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "329",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701742",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701742_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"verapamil\" outputclass=\"int-drug\">verapamil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  verapamil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "330",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Verapamil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701743",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701743_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"vilanterol\" outputclass=\"int-drug\">Vilanterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Vilanterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "331",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vilanterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701744",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701744_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  vinflunine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "332",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinflunine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701745",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701745_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">voriconazole</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  voriconazole  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "333",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701746",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701746_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  vortioxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "334",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vortioxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701747",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701747_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  xipamide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701747_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  xipamide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701747_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"xipamide\" outputclass=\"int-drug\">Xipamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Xipamide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   clomipramine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "335",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701748",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701748_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"zolmitriptan\" outputclass=\"int-drug\">zolmitriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  zolmitriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "336",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zolmitriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701749",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701749_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">Clomipramine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of overheating and dehydration when given with</ph> <ph otherprops=\"zonisamide\" outputclass=\"int-drug\">zonisamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid in children</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Clomipramine   potentially   increases   the risk of overheating and dehydration when given with   zonisamide .  Manufacturer advises avoid in children .    \n\n"
						}
					],
					"hasOrder": "337",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zonisamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701750",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701750_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"zuclopenthixol\" outputclass=\"int-drug\">zuclopenthixol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  clomipramine  and  zuclopenthixol  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/clomipramine#bnf_i1557280701750_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"clomipramine\" outputclass=\"int-heading-drug\">clomipramine</ph> and <ph otherprops=\"zuclopenthixol\" outputclass=\"int-drug\">zuclopenthixol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  clomipramine  and  zuclopenthixol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "338",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zuclopenthixol</title>"
					}
				}
			],
			"hasSearchLabel": " Clomipramine  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/clomipramine.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Clomipramine </title>"
			},
			"rdfs:label": "clomipramine"
		}
	]
}